4D Molecular Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
4D Molecular Therapeutics, Inc. (FDMT) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-02-29
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was $0.00.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was $0.00.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was $0.00.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$47.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$1.44M, a 383.27% decline from fiscal 2020.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $508.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | -$47.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | -$47.00K 10-Q · filed 2023-11-09 | -$791.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$47.00K 10-Q · filed 2023-08-09 | -$791.00K derived: sum of 3 quarters · filed 2023-08-09 | -$1.22M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$47.00K 10-Q · filed 2023-05-11 | -$791.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.22M derived: sum of 3 quarters · filed 2023-05-11 | -$965.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$744.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$1.17M derived: sum of 2 quarters · filed 2023-03-15 | -$918.00K derived: sum of 3 quarters · filed 2023-03-15 | -$1.44M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$427.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$174.00K derived: sum of 2 quarters · filed 2022-11-08 | -$695.00K 10-Q · filed 2022-11-08 | -$105.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$268.00K 10-Q · filed 2022-08-11 | $322.00K derived: sum of 3 quarters · filed 2022-08-11 | $490.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$521.00K 10-Q · filed 2022-05-12 | $69.00K derived: sum of 2 quarters · filed 2022-05-12 | $237.00K derived: sum of 3 quarters · filed 2022-05-12 | $86.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $758.00K derived: sum of 2 quarters · filed 2022-03-28 | $607.00K derived: sum of 3 quarters · filed 2022-03-28 | $508.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $17.00K derived: sum of 2 quarters · filed 2021-11-10 | -$82.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$250.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$99.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$146.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |